Drugs / MZE001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05249621 | Feb → Dec 2022 | — | Maze Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2023-12-11 | Maze Therapeutics | Regulatory Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease mazetx.com ↗ |
| 2023-03-22 | Maze Therapeutics | Results Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease mazetx.com ↗
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new data from an exploratory muscle biopsy cohort of its Phase 1 clinical trial of MZE001 in healthy volunteers to evaluate the effects of MZE001 on glycogen synthesis. |
| 2023-02-27 | Maze Therapeutics | Results Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease mazetx.com ↗
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced positive results from the company’s Phase 1 clinical trial of MZE001 in healthy volunteers. |
| 2022-12-15 | Maze Therapeutics | Results Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease mazetx.com ↗
Topline data demonstrated that administration of MZE001 was well-tolerated at single and multiple doses, with a PK profile supporting twice-daily dosing. |
| 2022-08-31 | Maze Therapeutics | Regulatory Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease mazetx.com ↗
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to MZE001, the company’s investigational product for the treatment of Pompe disease. |
| 2022-02-10 | Maze Therapeutics | Results Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease mazetx.com ↗
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new preclinical data supporting the advancement of MZE001, which aims to address Pompe disease by reducing pathologic glycogen accumulation through the inhibition of muscle glycogen synthase (GYS1). |
All press releases naming this drug 11 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MZE001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05249621 ↗ |
| Action | Inhibit | “Small molecule inhibitor of muscle glycogen synthase” NCT05249621 ↗ |
| Modality | Small molecule | “Small molecule inhibitor of muscle glycogen synthase” NCT05249621 ↗ |
| Route | Oral | “orally administered MZE001” NCT05249621 ↗ |